CytoDyn Inc. CYDY
OTC PK
| 08/31/2026 | 05/31/2026 | 02/28/2026 | 11/30/2025 | 08/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 7.79M | 7.45M | 7.00M | 6.87M | 7.36M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.78M | 23.15M | 21.42M | 19.12M | 17.72M |
| Operating Income | -24.78M | -23.15M | -21.42M | -19.12M | -17.72M |
| Income Before Tax | -57.10M | -42.70M | -38.79M | -38.86M | -21.02M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -57.10 | -42.70 | -38.79 | -38.86 | -21.02 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -57.10M | -42.70M | -38.79M | -38.86M | -21.02M |
| EBIT | -24.78M | -23.15M | -21.42M | -19.12M | -17.72M |
| EBITDA | -24.75M | -23.13M | -21.40M | -19.10M | -17.70M |
| EPS Basic | -0.04 | -0.03 | -0.03 | -0.03 | -0.02 |
| Normalized Basic EPS | -0.02 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.05 | -0.04 | -0.04 | -0.04 | -0.02 |
| Normalized Diluted EPS | -0.02 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 5.29B | 5.16B | 5.03B | 4.98B | 4.94B |
| Average Diluted Shares Outstanding | 5.29B | 5.16B | 5.03B | 4.98B | 4.94B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |